FDA shuts down Intarcia's requests to deviate from typical post-CRL hearing process
The FDA will go ahead with a regular advisory committee hearing process for battered Intarcia’s twice-yearly type 2 diabetes drug, known as ITCA 650, and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
